Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.


Director, Pediatric Gastroenterology; Vice Chairman, Clinical Development and Research Affairs, Goryeb Children's Hospital/Atlantic Health, New Jersey; Professor of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, New York

Joel R. Rosh received an Honors Degree from Brown University and his Medical Degree from the Albert Einstein College of Medicine in New York. His postdoctoral training included an internship and residency at the Children’s Hospital of New York–Columbia Presbyterian Medical Center and a Fellowship in Pediatric Gastroenterology at the Mount Sinai Medical Center in New York. He remained on faculty at Mount Sinai until 1994 when he moved to the Goryeb Children’s Hospital/Atlantic Health in Morristown, NJ where he founded the Division of Pediatric Gastroenterology and the Pediatric IBD Center.

Dr. Rosh is a member of the National Board of Trustees and has served on numerous national committees of the Crohn’s & Colitis Foundation. He has been a National Councilor for NASPGHAN and has been on multiple editorial boards including that of the Journal of Pediatric Gastroenterology and Nutrition and the Journal of Clinical Gastroenterology. Dr. Rosh has been honored as the national and local Crohn’s & Colitis Foundation Physician of the Year and has received the New Jersey Pediatric Society Physician Recognition Award. Dr. Rosh’s current research focus is the safety and efficacy of standard as well as emerging pharmacotherapy in Pediatric IBD.


Dr. Rosh reports the following:
  • Grant/Research Support: Abbvie, Janssen
  • Consultant/Advisory Board: Abbvie, BMS, Celgene, Eli Lilly, Janssen, Pfizer